Construction of eukaryotic expression vector of siRNA specific to bcr/abl fusion gene
Xiangrong Guo
Abstract
Xiangrong Guo
Abstract
Objective:To construct eukaryotic expression vector of siRNA specific to bcr/abl and to initially investigate the effect of recombinant plasmid on bcr/abl and P210 protein expression in K562 cells.Methods:siRNA( small interfering RNA)was designed according to the tuschl′s principle of RNA i-based medicine,and was converted into cDNA coding expression of shRNA(small hairp in RNA) of siRNA for bcr/a blfusion gene.The cDNA was synthesized and inserted into plasmid pTER.The pTER117 of recombinant plasmid being eukaryotic expression vector was controlled by the H1 promoter of RNA polymerase,identified by the restriction map and the sequence analysis,and transfected into K562 cells by lipofectamine.Expression of bcr/abl mRNA was assayed by RT-PCR,expression of P210 protein w as detected by immuno histochemistry.Results:The pTER117 of recombinant plasmid identified by the restriction map and the sequence analysis completely coincided with the designs.24 hours after transfection in K562 cells,the recombinant plasmid could down regulate the expression of the bcr/abl mRNA and bcr/abl protein(P210) in K562 cells.Conclusion:The siRNA eukaryotic expression vector against bcr/abl mRNA has been successfully conctructed,and it effectively inhibits the expression of bcr/abl in K562 cells.
A significance statement is not available in the OpenAlex record.
A contribution statement is not available in the OpenAlex record.
Method details are not available in the OpenAlex metadata.
Findings are not separately available in the OpenAlex metadata.
Limitations are not available in the OpenAlex metadata.
Application details are not available in the OpenAlex metadata.
Objective:To construct eukaryotic expression vector of siRNA specific to bcr/abl and to initially investigate the effect of recombinant plasmid on bcr/abl and P210 protein expression in K562 cells.Methods:siRNA( small interfering RNA)was designed according to the tuschl′s principle of RNA i-based medicine,and was converted into cDNA coding expression of shRNA(small hairp in RNA) of siRNA for bcr/a blfusion gene.The cDNA was synthesized and inserted into plasmid pTER.The pTER117 of recombinant plasmid being eukaryotic expression vector was controlled by the H1 promoter of RNA polymerase,identified by the restriction map and the sequence analysis,and transfected into K562 cells by lipofectamine.Expression of bcr/abl mRNA was assayed by RT-PCR,expression of P210 protein w as detected by immuno histochemistry.Results:The pTER117 of recombinant plasmid identified by the restriction map and the sequence analysis completely coincided with the designs.24 hours after transfection in K562 cells,the recombinant plasmid could down regulate the expression of the bcr/abl mRNA and bcr/abl protein(P210) in K562 cells.Conclusion:The siRNA eukaryotic expression vector against bcr/abl mRNA has been successfully conctructed,and it effectively inhibits the expression of bcr/abl in K562 cells.
Key concepts: Molecular biology, Lipofectamine, Small hairpin RNA, K562 cells, Complementary DNA, Transfection, Small interfering RNA, Biology